A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Recruiting · Phase 1 · NCT06469281
Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
At a glance
- Research payments reported, 2025
- $996,275
- U.S. investigators named
- 6
- Sites paid
- 8
- Planned or actual enrollment
- 90
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- 27T51 (other), Cemiplimab (drug), Bevacizumab (drug)
- Dates
- Started 2024-08-06; completion 2030-05-27
- Results posted
- Not yet
This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. This study has two (2) major parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion. The aim of the dose escalation part will be to test the safety of 27T51 in a small number of participants to find the highest dose given to humans without unacceptable side effects. The aim of the dose expansion part will be to test 27T51 at the established dose level(s) from the dose escalation part and may …
From ClinicalTrials.gov, last updated 2026-02-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $996,275 in research payments for this study in 2025 (39 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Oladapo O. Yeku, M.D, PHD Hematology & Oncology · Boston, MA
- Martin E. Gutierrez, MD Medical Oncology · Hackensack, NJ
- Emese Zsiros, MD Gynecologic Oncology · Buffalo, NY
- Jason Luke, M.D. Hematology & Oncology · Pittsburgh, PA
- Sarah Taylor OB-GYN (Obstetrics & Gynecology) · Pittsburgh, PA
- Bradley Hunter, MD, MPH Medical Oncology · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Health Research Inc Roswell PArk Division $315,075
- Hackensack University Medical Center, NJ $200,488
- Dana-Farbermass General Brigham Ca $114,708
- University of Pittsburgh of the Commonwealth System of Higher Education $112,453
- University of Pittsburgh of the Commonwealth System of Higher Educatio $103,910
- Dana-Farbermass General Brigham Cancer Center Inc $96,852
- Intermountain Health Mckay-Dee Hospital, UT $42,550
- Dana-Farber Mass General Brigham Ca $10,240
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.